(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination - 2Must-Have Wellness Gear: What to Purchase for Successful Exercises
- 3Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- 42024 Style: The It-Things You Want in Your Closet
- 5Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- Palestinians reel under winter rains as Israel blocks Gaza shelter supplies
- Individual Preparation Administrations to Raise Your Wellness Process
- Which Switch Game Do You Suggest? Share Your Decision
- Antivirus Programming for Exhaustive Security
- Japan deploys the military to counter a surge in bear attacks
- Step by step instructions to Guarantee Your Fender bender Legal counselor has Areas of strength for a Record
- Inconceivable Spots To Stargaze All over The Planet
- Man triggers smoke bomb during failed crypto robbery
